Inactive Instrument

Press Releases Biodel Inc Nasdaq

Equities

US09064M1053

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2023	CAC40: in green, gains over 2% on a weekly basis	CF
2023	CAC40: PMI and ISM data point to 22nd week of gains	CF

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ALBIREO PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	23-03-02	AQ
Albireo Pharma, Inc. - FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay in Alagille Syndrome	23-02-15	AQ
ALBIREO PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-02-14	AQ
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome	23-02-14	AQ
ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO	23-01-24	BU
ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO	23-01-10	BU
ALERT: The M&A Class Action Firm Announces the Investigation of Albireo Pharma, Inc. - ALBO	23-01-09	PR
Shareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with Ipsen	23-01-09	PR
ALBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Albireo Pharma, Inc. Is Fair to Shareholders	23-01-09	BU
Albireo Pharma : Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases - Form 8-K	23-01-09	PU
ALBIREO PHARMA, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-01-09	AQ
Albireo Pharma : Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases	23-01-09	PU
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	22-12-20	AQ
Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA	22-12-19	AQ
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer and Craig Hopkinson, M.D., to Board of Directors	22-12-07	AQ
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	22-12-06	AQ
ALBIREO PHARMA, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-12-06	AQ
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors	22-12-06	AQ
Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2	22-11-30	GL
Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2	22-11-30	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Biodel Inc Nasdaq

Equities

US09064M1053

Press Releases

Filters